{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Neumann C"],"funding":["Bundesministerium für Bildung und Forschung","ERA PerMed","Bundesministerium für Gesundheit","Universitätsklinikum Jena"],"pagination":["2383-2395"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12675558"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["53(6)"],"pubmed_abstract":["Purpose
Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment.Methods
We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predic"],"journal":["Infection"],"pubmed_title":["Clinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients-a post-hoc analysis of the HYPRESS trial."],"pmcid":["PMC12675558"],"funding_grant_id":["ANR-21-PERM-0005","01KU2209","ZMI5-2522FSB902"],"pubmed_authors":["Neumann C","Kiehntopf M","Annane D","Garchon HJ","Meybohm P","Chelly-Dagdia Z","Heming N","Meersch-Dini M","SepNet Critical Care Trials Group","Flores C","Grassin Delyle S","Mahmoud J","Bouneb R","Bauer M","Frank B","Diallo K","Hellali R","Vovy MA","Frank S","Brenner T","Konig R","iRECORDS collaborators","Elke G","Moine P","Abdelghany SA","Hash RY","Nassar YS","Bloos F","Elwi HM","Hunzinger N","Leitner M","Maxime V","Zeitouni K","Villar J","Hinske L","Kaasch A","Habler K","Roquencourt C","Aly MAK","Lamy E","Loeffler M","Briegel J","Scharf-Janssen C","Lange D","Fleuriet J","Vogeser M","Elgengeehy SM","Weigand M","Elansary MG","Oswald M","Bogatsch H","Putensen C","Kluge S","Adling-Ehrhardt M","Grundling M"],"additional_accession":[]},"is_claimable":false,"name":"Clinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients-a post-hoc analysis of the HYPRESS trial.","description":"Purpose
Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment.Methods
We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predic","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T22:21:27.582Z","creation":"2026-05-22T03:16:23.549Z"},"accession":"S-EPMC12675558","cross_references":{"pubmed":["40447978"],"doi":["10.1007/s15010-025-02569-x"]}}